Vyome Shares Jump After Valuation Places Lead Asset Near $1 Billion on Phase 3 Success
Vyome Holdings (NASDAQ:HIND) saw its stock climb 70% following an independent valuation that pegs the company’s lead investigational therapy, VT-1953, at roughly $1 billion contingent on successful Phase 3 results. The analysis, commissioned by Vyome and produced by Destum Partners, models a U.S. total addressable market near $2.2 billion and forec…